5-氨基乙酰丙酸盐酸盐 (5-ALA) 的商品名为 Gleolan，是一种口服荧光团药物，用于增强癌组织与健康组织的视觉区分，主要是在高级别神经胶质瘤的手术切除过程中。尽管在术前给予，5-ALA 对整个围手术期的麻醉护理具有重要意义。本文回顾了接受口服 5-ALA 的患者的药理学、安全性问题和围手术期注意事项。尽管美国食品和药物管理局于 2017 年批准临床使用，但此后发表的研究和病例报告进一步描述了该药物的副作用药物及其机制和药代动力学。减轻 5-ALA 可能的副作用需要了解其基本机制以及有针对性的围手术期计划和沟通。服用这种药物可能会导致恶心和呕吐、光过敏、肝酶血清浓度增加和低血压。接受 5-ALA 治疗的患者在服用后的前 48 小时内必须避免长时间光照，并应避免使用其他光敏剂（补充视频文件/视频摘要）。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

5-Aminolevulinic acid hydrochloride (5-ALA), available under the trade name Gleolan, is an orally administered fluorophore drug used to enhance visual differentiation of cancerous tissue from healthy tissue, primarily during surgical resection of high-grade gliomas. Although given preoperatively, 5-ALA has important implications for anesthetic care throughout the perioperative period. This article reviews pharmacology, safety concerns, and perioperative considerations for patients who receive oral 5-ALA.Although approved for clinical use by the United States Food and Drug Administration in 2017, studies and case reports published since then have further delineated side effects of this medication and its mechanisms and pharmacokinetics.Mitigating the possible side effects of 5-ALA requires an understanding of its basic mechanism as well as focused perioperative planning and communication. Administration of this medication may result in nausea and vomiting, photosensitivity, increases in serum concentration of liver enzymes, and hypotension. Patients who receive 5-ALA must be protected from prolonged light exposure during the first 48 h after consumption and administration of other photosensitizing agents should be avoided (Supplemental Video File/Video abstract).Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.